Novel strategies for steroid-refractory acute graft-versus-host disease

Research output: Contribution to journalArticle

Abstract

Purpose of review: Graft-versus-host disease is one of the commonest complications of allogeneic bone marrow or peripheral blood stem cell transplantation. This review will cover advances in the pathophysiology of graft-versus-host disease and new agents under investigation for the treatment of this disorder. Patients developing graft-versus-host disease who fail to respond to steroids have a poor prognosis. In this group of people, morbidity and mortality are very high. Recent findings: Novel agents are currently under investigation for the treatment of such devastating disorders. Pentostatin, denileukin diftitox, mycophenolate moferil, extracorporeal photopheresis, and several monoclonal antibodies have been used, some of them with encouraging results. Summary: As supportive care improves and new agents are added to the armamentarium against steroid-refractory acute graft-versus-host disease, the prognosis of this entity may start to change. Patients with this complication after transplantation should be enrolled, whenever possible, in clinical trials to find effective therapies.

Original languageEnglish (US)
Pages (from-to)40-44
Number of pages5
JournalCurrent Opinion in Hematology
Volume12
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

Graft vs Host Disease
Steroids
Photopheresis
Pentostatin
Peripheral Blood Stem Cell Transplantation
Therapeutics
Transplantation
Bone Marrow
Monoclonal Antibodies
Clinical Trials
Morbidity
Mortality

Keywords

  • Acute graft-versus-host disease
  • Denileukin diftitox
  • Mycophenolate mofetil
  • Pentostatin
  • Steroid-refractory graft-versus-host disease

ASJC Scopus subject areas

  • Hematology

Cite this

@article{f7827d47433b4b56be552a1b98371bdd,
title = "Novel strategies for steroid-refractory acute graft-versus-host disease",
abstract = "Purpose of review: Graft-versus-host disease is one of the commonest complications of allogeneic bone marrow or peripheral blood stem cell transplantation. This review will cover advances in the pathophysiology of graft-versus-host disease and new agents under investigation for the treatment of this disorder. Patients developing graft-versus-host disease who fail to respond to steroids have a poor prognosis. In this group of people, morbidity and mortality are very high. Recent findings: Novel agents are currently under investigation for the treatment of such devastating disorders. Pentostatin, denileukin diftitox, mycophenolate moferil, extracorporeal photopheresis, and several monoclonal antibodies have been used, some of them with encouraging results. Summary: As supportive care improves and new agents are added to the armamentarium against steroid-refractory acute graft-versus-host disease, the prognosis of this entity may start to change. Patients with this complication after transplantation should be enrolled, whenever possible, in clinical trials to find effective therapies.",
keywords = "Acute graft-versus-host disease, Denileukin diftitox, Mycophenolate mofetil, Pentostatin, Steroid-refractory graft-versus-host disease",
author = "{Bolanos Meade}, {F Javier} and Vogelsang, {Georgia Boyce}",
year = "2005",
month = "1",
doi = "10.1097/01.moh.0000148763.12733.bb",
language = "English (US)",
volume = "12",
pages = "40--44",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Novel strategies for steroid-refractory acute graft-versus-host disease

AU - Bolanos Meade, F Javier

AU - Vogelsang, Georgia Boyce

PY - 2005/1

Y1 - 2005/1

N2 - Purpose of review: Graft-versus-host disease is one of the commonest complications of allogeneic bone marrow or peripheral blood stem cell transplantation. This review will cover advances in the pathophysiology of graft-versus-host disease and new agents under investigation for the treatment of this disorder. Patients developing graft-versus-host disease who fail to respond to steroids have a poor prognosis. In this group of people, morbidity and mortality are very high. Recent findings: Novel agents are currently under investigation for the treatment of such devastating disorders. Pentostatin, denileukin diftitox, mycophenolate moferil, extracorporeal photopheresis, and several monoclonal antibodies have been used, some of them with encouraging results. Summary: As supportive care improves and new agents are added to the armamentarium against steroid-refractory acute graft-versus-host disease, the prognosis of this entity may start to change. Patients with this complication after transplantation should be enrolled, whenever possible, in clinical trials to find effective therapies.

AB - Purpose of review: Graft-versus-host disease is one of the commonest complications of allogeneic bone marrow or peripheral blood stem cell transplantation. This review will cover advances in the pathophysiology of graft-versus-host disease and new agents under investigation for the treatment of this disorder. Patients developing graft-versus-host disease who fail to respond to steroids have a poor prognosis. In this group of people, morbidity and mortality are very high. Recent findings: Novel agents are currently under investigation for the treatment of such devastating disorders. Pentostatin, denileukin diftitox, mycophenolate moferil, extracorporeal photopheresis, and several monoclonal antibodies have been used, some of them with encouraging results. Summary: As supportive care improves and new agents are added to the armamentarium against steroid-refractory acute graft-versus-host disease, the prognosis of this entity may start to change. Patients with this complication after transplantation should be enrolled, whenever possible, in clinical trials to find effective therapies.

KW - Acute graft-versus-host disease

KW - Denileukin diftitox

KW - Mycophenolate mofetil

KW - Pentostatin

KW - Steroid-refractory graft-versus-host disease

UR - http://www.scopus.com/inward/record.url?scp=13244292532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13244292532&partnerID=8YFLogxK

U2 - 10.1097/01.moh.0000148763.12733.bb

DO - 10.1097/01.moh.0000148763.12733.bb

M3 - Article

C2 - 15604890

AN - SCOPUS:13244292532

VL - 12

SP - 40

EP - 44

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 1

ER -